Anakinra, a new pharmacotherapeutic approach to treating rheumatoid arthritis

Today's Therapeutic Trends

Volumn 21, Issue 1, 2003, Pages 49-59

  Haraoui, Boulos ^a   Keystone, Edward C ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; BINDING KINETICS; BOLUS INJECTION; CLINICAL TRIAL; COMPETITIVE INHIBITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INHIBITION KINETICS; INJECTION SITE; JOINT DESTRUCTION; LEUKOPENIA; REVIEW; RHEUMATOID ARTHRITIS; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0037374042     PISSN: 07412320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Harris ED Jr.: Rheumatoid arthritis: Pathophysiology and implications for therapy. N. Engl. J. Med. 322:1277-1289, 1990.
2. Choy EH and Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344:907-916, 2001.
3. Dinarello CA: Biologic basis for interleukin 1 in disease. Blood 87:2095-2147, 1996.
4. Dayer JM, De-Rochemontix B, Burrus B, et al.: Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J. Clin. Invest. 77:645-648, 1986.
5. Hannum CH, Wilcox CJ, Arend WP, et al.: Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:336-340, 1990.
6. Arend WP: Interleukin-1 receptor antagonist - A new member of the interleukin-1 family. J. Clin. Invest. 88:1445-1451, 1991.
7. van Lent PLEM, van de Loo FAJ, Astrid EM, et al.: Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex in mice. J. Rheumatol. 22:2250-2258, 1995.
8. Henderson B and Pettipher ER: Comparison of the in vivo inflammatory activities after intra-articular injection of natural and recombinant IL-1 alpha and IL-1 beta in the rabbit. Biochem. Pharmacol. 37:4171-40176, 1988.
9. Ghivizzani SC, Kang R, Georgescu HI, et al.: Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J. Immunol. 159:3604-3612, 1997.
10. Hom JT, Cole H and Bendele AM: Interleukin 1 enhances the development of spontaneous arthritis in MRL/1pr mice. Clin. Immumol. Immunopathol. 55:109-119, 1990.
11. van de Loo FA, Arntz OJ, Otterness IG and van den Berg WB: Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin 1 antibodies in experimental arthritis. J. Rheumatol. 19:348-356, 1992.
12. Eastgate JA, Symons JA, Wood NC, et al.: Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet ii:706-709, 1988.
13. Miyasaka N, Sato K, Goto M, et al.: Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients: Possible involvement in joint destruction. Arthritis Rheum. 31:480-486, 1988.
14. van de Loo FAJ, Joosten LAB, van Lent PLEM, et al.: Role of interleukin-1 tumor necrosis factor-α and interleukin-6 in cartilage proteoglycan metabolism and destruction: Effect of in-situ blocking in murine antigen and zymosan-induced arthritis. Arthritis Rheum. 38:164-172, 1995.
15. van den Berg WB: Joint inflammation and cartilage destruction may occur uncoupled. Springer Semin. Immunopathol. 20:149-164, 1998.
16. Kineret™ product monograph, Amgen Canada Inc., May 2002.
17. Bresnihan B, Alvaro-Garcia JM, Cobby M, et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis-Rheum. 41:2196-2204, 1998.
18. Jiang Y, Genant HK, Watt I, et al.: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 43:1001-1009, 2000.
19. Nuki G, Bresnihan B, Moraye BB, et al.: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum. 46:2838-2846, 2002.
20. Cohen S, Hurd E, Cush J, et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum. 46:614-624, 2002.
21. Cohen SB, Moreland LW, Cush JJ, et al.: Kineret™ (anakinra) (recombinant interleukin-1 receptor antagonist): A large placebo controlled efficacy trial of Kineret™ in patients with erosive rheumatoid arthritis. Ann. Rheum. Dis. 61(Suppl.): S173, 2002.
22. Shergy WJ, Cohen S, Greenwald M, et al.: Anakinra (Kineret™) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis. Late-breaking abstract presented at the American College of Rheumatology meeting, New Orleans, Otober 24-29, 2002.
23. Fleischman R, Tesser J, Schechtman J, et al.: A safety trial of anakinra: Recombinant interleukin-1 receptor antagonist (IL-1Ra) in a large placebo controlled heterogeneous population of patients with rheumatoid arthritis. Arthritis-Rheum. 44(Suppl.):S84, 2001.
24. Schiff M, Hartman S, Devittorio G, et al.: The safety of Kineret (anakinra) in high risk patients (Abstr.). Ann. Rheum. Dis. 61:173, 2002.
25. Schiff M, Bulpitt K, Weaver A, et al.: Safety of combination therapy with Kineret™ (anakinra) and etanercept in patients with rheumatoid arthritis (Abstr.). Ann. Rheum. Dis. 61(Suppl.):185, 2002.
26. Moreland LW: Up-to-the-minute data. Highlights of combination therapy. 177: IL-1 blockade. A new promise in the treatment of RA. Satellite symposium at the American College of Rheumatology meeting, New Orleans, October 24-29, 2002.
27. Caldwell JR, Offenberg H, Furst D, et al.: A phase I safety study of combination treatment with pegylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and anakinra (interleukin-1 receptor antagonist, IL-1RA) in patients with rheumatoid arthritis (Abstr.). Arthritis Rheum. 44(Suppl.):S370, 2001.
28. Reiff A, Porras O, Rudge S, et al.: Preliminary data from a study of Kineret™ (anakinra) in children with juvenile rheumatoid arthritis. Arthritis Rheum. 46(Suppl.):S215, 2002.